Lars Abrahmsen Biography and Net Worth



Lars Abrahmsen, Ph.D. has served as our Senior Vice President, Chief Scientific Officer since October 2014. Dr. Abrahmsen has more than 30 years of experience in research and drug development in the pharmaceutical industry, both with small molecules and biopharmaceuticals. Beginning with postdoctoral work at Genentech, he has also worked at Biovitrum, Pharmacia&Upjohn, Pharmacia and KabiGen. More recently he served as Chief Scientific Officer at Affibody from 2004-2010 and as SVP of Protein Therapeutics at Algeta from 2010-2013. Dr. Abrahmsen has experience from discovery research to preclinical development and has primarily focused on projects within oncology and metabolic diseases. Dr. Abrahmsen received a Ph.D. in Biochemistry and an M.S. in Chemistry, both from the Royal Institute of Technology in Stockholm, Sweden.

How old is Lars B. Abrahmsen?

Dr. Abrahmsen is currently 67 years old. There are 3 older executives and no younger executives at Aprea Therapeutics. Learn More on Lars B. Abrahmsen's age.

How do I contact Lars B. Abrahmsen?

The corporate mailing address for Dr. Abrahmsen and other Aprea Therapeutics executives is 535 BOYLSTON STREET, BOSTON MA, 02116. Aprea Therapeutics can also be reached via phone at 617-463-9385 and via email at [email protected]. Learn More on Lars B. Abrahmsen's contact information.

Has Lars B. Abrahmsen been buying or selling shares of Aprea Therapeutics?

Lars B. Abrahmsen has not been actively trading shares of Aprea Therapeutics over the course of the past ninety days. Most recently, Lars B. Abrahmsen sold 2,500 shares of the business's stock in a transaction on Friday, October 1st. The shares were sold at an average price of $97.80, for a transaction totalling $244,500.00. Learn More on Lars B. Abrahmsen's trading history.

Who are Aprea Therapeutics' active insiders?

Aprea Therapeutics' insider roster includes Lars Abrahmsen (SVP), Eyal Attar (SVP), and Gregory Korbel (SVP). Learn More on Aprea Therapeutics' active insiders.

Are insiders buying or selling shares of Aprea Therapeutics?

In the last year, Aprea Therapeutics insiders bought shares 4 times. They purchased a total of 13,938 shares worth more than $86,719.14. The most recent insider tranaction occured on March, 13th when CFO John P Hamill bought 1,010 shares worth more than $7,362.90. Insiders at Aprea Therapeutics own 20.9% of the company. Learn More about insider trades at Aprea Therapeutics.

Information on this page was last updated on 3/13/2024.

Lars B. Abrahmsen Insider Trading History at Aprea Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/1/2021Sell2,500$97.80$244,500.00View SEC Filing Icon  
See Full Table

Lars B. Abrahmsen Buying and Selling Activity at Aprea Therapeutics

This chart shows Lars B Abrahmsen's buying and selling at Aprea Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Aprea Therapeutics Company Overview

Aprea Therapeutics logo
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Read More

Today's Range

Now: $6.50
Low: $5.91
High: $6.50

50 Day Range

MA: $6.36
Low: $5.09
High: $8.46

2 Week Range

Now: $6.50
Low: $2.78
High: $8.85

Volume

11,162 shs

Average Volume

35,867 shs

Market Capitalization

$24.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05